|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,970 DKK | +0.79% |
|
-2.96% | -8.58% |
| Apr. 16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
| Apr. 16 | Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 | CI |
(Reuters) - Danish biotech Genmab has agreed to buy U.S. cancer drug maker ProfoundBio for $1.8 billion, the two companies said on Wednesday.
The acquisition will give Genmab worldwide rights to three candidates in clinical development, they added.
The all-cash transaction is subject to adjustment for ProfoundBio's closing net debt and transaction expenses.
(Reporting by Elviira Luoma, editing by Terje Solsvik)
| 1st Jan change | Capi. | |
|---|---|---|
| -8.58% | 18.15B | |
| -2.53% | 103B | |
| +1.75% | 95.28B | |
| +1.46% | 22.15B | |
| -15.61% | 21.02B | |
| -38.74% | 16.73B | |
| -12.70% | 16.05B | |
| +5.42% | 13.68B | |
| +34.19% | 12.17B | |
| -24.02% | 8.24B |
GENMAB A/S 
